Fig. 4: Clinical outcomes in the primary cohort according to timing of tissue collection with respect to first Tmab treatment. | Nature Medicine

Fig. 4: Clinical outcomes in the primary cohort according to timing of tissue collection with respect to first Tmab treatment.

From: Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Fig. 4

a, ORR in the study according to tissue collected before or after/during first Tmab treatment. b, OS analyzed over the course of the study according to tissue collected before or after/during first Tmab treatment. a, Error bars represent 95% CI; the center of error bars indicates ORR. aIncludes data for the response-evaluable set (all randomized patients who received at least one dose of study drug and had measurable tumors based on independent central review at baseline).

Back to article page